• 1
    Aso Y, Akaza H, Kotake T et al. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. Eur. Urol. 1995; 27: 1049.
  • 2
    Naito S, Koga H, Yamaguchi A et al. Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer. J. Urol. 2008; 179: 48590.
  • 3
    Castelao JE, Yuan JM, Gago-Dominguez M et al. Carotenoids/Vitamin C and smoking-related bladder caner. Int. J. Cancer 2004; 110: 41723.
  • 4
    Jacobs EJ, Henion AK, Briggs PJ et al. Vitamin C and Vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women. Am. J. Epidemiol. 2002; 156: 100210.
  • 5
    Michaud DS, Spiegelman D, Clinton SK et al. Prospective study of dietary supplements, macronutrients, micronutrients, and risk of bladder cancer in US men. Am. J. Epidemiol. 2000; 152: 114553.
  • 6
    Castelao JE, Yuan JM, Gago-Dominguez M et al. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br. J. Cancer 2000; 82: 13649.
  • 7
    Brennan P, Bogillot O, Cordier S et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int. J. Cancer 2000; 86: 28994.
  • 8
    Bjerregaard BK, Raaschou-Nielsen O, Sorensen M et al. Tobacco smoke and bladder cancer-in the European Prospective Investigation into Cancer and Nutrition. Int. J. Cancer 2006; 119: 241216.
  • 9
    Hinotsu S, Akaza H, Miki T et al. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. Int. J. Urol. 2009; 16: 649.
  • 10
    Brown FM. Urine cytology. Is it still the gold standard for screening? Urol. Clin. North Am. 2000; 27: 2537.
  • 11
    Raab SS, Slagel DD, Jensen CS et al. Low-grade transitional cell carcinoma of the urinary bladder: application of select cytologic criteria to improve accuracy. Mod. Pathol. 1996; 9: 22532.
  • 12
    Miyanaga N, Akaza H, Tsukamoto T et al. Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria. Int. J. Urol. 1999; 6: 1737.
  • 13
    Miyanaga N, Akaza H, Kameyama S et al. Significance of the BTA test in bladder cancer: a multicenter trial. BTA study group Japan. Int. J. Urol. 1997; 4: 55760.
  • 14
    Grossman HB, Soloway M, Messing E et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2007; 295: 299305.
  • 15
    Goessl C, Knispel HH, Miller K et al. Is routine excretory urography necessary at first diagnosis of bladder cancer? J. Urol. 1997; 157: 4801.
  • 16
  • 17
    Ozono S, Hinotsu S, Tabata S et al. Treated natural history of superficial bladder cancer. Jpn J. Clin. Oncol. 2001; 31: 53640.
  • 18
  • 19
    Van Der Meijden A, Oosterlinck W, Brausi M et al. Significance of bladder biopsies in Ta,T1 bladder tumors: a report of the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur. Urol. 1999; 35: 26771.
  • 20
    Mungan MU, Canda AE, Tuzel E et al. Risk factor for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. Eur. Urol. 2005; 48: 7603.
  • 21
    Shelfo SW, Brady JD, Soloway MS. Transurethral resection of bladder cancer. The mainstay of treatment. Atlas Urol. Clin. North Am. 1997; 5: 114.
  • 22
    Sakamoto N, Tsuneyoshi M, Naito S et al. An adequate sampling of the prostate to identify prostatic involvement by urothelial carcinoma in bladder cancer patients. J. Urol. 1993; 149: 31821.
  • 23
    Schwaibold HE, Sivalingam S, May F et al. The value of a second transurethral resection for T1 bladder cancer. BJU Int. 2006; 97: 1199201.
  • 24
    Sivalingam S, Probert JL, Schwaibold H. The role of repeat transurethral resection in the management of high-risk superficial transitional cell bladder cancer. BJU Int. 2005; 96: 75962.
  • 25
    Miladi M, Peyromaure M, Zerbib M et al. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur. Urol. 2003; 43: 2415.
  • 26
    Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J. Urol. 1999; 162: 746.
  • 27
    Sylvester RJ, Van Der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 2006; 49: 46677.
  • 28
    Solsona E, Iborra I, Dumont R et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J. Urol. 2000; 163 (3 Pt 1): 6859.
  • 29
    Solsona E, Iborra I, Ric JV et al. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J. Urol. 1999; 161: 11203.
  • 30
    Okamura K, Ono Y, Kinukawa T et al. Randomized study of single early instillation of (2"R)-4′-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 2002; 94: 23638.
  • 31
    Rajala P, Kaasinen E, Raitanen M et al. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study – FinnBladder III long-term results. J. Urol. 2002; 168: 9815.
  • 32
    Sylvester RJ, Oosterlinck W, Van Der Meijden APM. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol. 2004; 171: 218690.
  • 33
    Akaza H, Isaka S, Koiso K et al. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group. Cancer Chemother. Pharmacol. 1987; 20 (Suppl): S916.
  • 34
    Akaza H, Koiso K, Kotake T et al. Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother. Pharmacol. 1992; 30 (Suppl): S1520.
  • 35
    Kuroda M, Niijima T, Kotake T et al. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer – The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml. Eur. Urol. 2004; 45: 6005.
  • 36
    Hinotsu S, Akaza H, Ohashi Y et al. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 1999; 86: 181826.
  • 37
    Witjes JA, Hendricksen K. Intravesical pharmacotherapy for non-muscleinvasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur. Urol. 2008; 53: 4552.
  • 38
    Sylvester RJ, Van Der Meijden AP, Lamm D. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 2002; 168: 196470.
  • 39
    Akaza H, Hinotsu S, Aso Y et al. Bacillus Calmette-Gu rin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. Cancer 1995; 75: 5529.
  • 40
    Akaza H, Koiso K, Ozono S et al. A clinical study of PMCJ-9 (Bacillus Calmette-Gu rin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder. Jpn J. Clin. Oncol. 2003; 33: 38290.
  • 41
    Hinotsu S, Akaza H, Isaka S et al. Sustained prophylactic effect of intravesical bacille Calmette-Gu rin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. Urology 2006; 67: 5459.
  • 42
    Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J. Urol. 2005; 174: 12427.
  • 43
    Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol. 2003; 169: 905.
  • 44
    Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 2000; 163: 11249.
  • 45
    Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J. Urol. 2001; 166: 12969.
  • 46
    Joudi FN, O'Donnell MA. Second-line intravesical therapy versus cystectomy for bacille Calmette-Gu rin (BCG) failures. Curr. Opin. Urol. 2004; 14: 2715.
  • 47
    Solsona E, Iborra I, Rubio J et al. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. BJU Int. 2004; 94: 125862.
  • 48
    Van Der Meijden APM, Sylvester R, Oosterlinck W et al. EAU guidelines on the diagnosis and treatment of urpthelial carcinoma in situ. Eur. Urol. 2005; 48: 36371.
  • 49
    Hall CG, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (Stage Ta, T1, and Tis): 2007 update. J. Urol. 2007; 178: 231430.
  • 50
    NCCN Clinical Practice Guideline in Oncology, Bladder Cancer. MS-4, 2008. Available from the URL:
  • 51
    Bladder Cancer Treatment. Stage 0 Bladder Cancer. Available from the URL:
  • 52
    Sylvester RJ, Van Der Meijden APM, Witjes JA et al. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol. 2005; 174: 869.
  • 53
    Jakse G, Hall R, Bono A et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur. Urol. 2001; 40: 14450.
  • 54
    Persad R, Lamm D, Brausi M et al. Current approaches to the management of non-muscle invasive bladder cancer: comparison of current guidelines and recommendations. Eur. Urol. 2008; 7 (Suppl): 63750.
  • 55
    Coplen DE, Marcus MD, Myers JA et al. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J. Urol. 1990; 144: 6527.
  • 56
    Barentsz JO, Witjes JA, Ruijs JH. What is new in bladder cancer imaging. Urol. Clin. North Am. 1997; 24: 583602.
  • 57
    Jagar GJ, Barentsz JO, Oosterhof GO et al. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional T1-weighted magnetization-prepared-rapid gradient-echo sequence. Am. J. Roentogenol. 1996; 167: 15037.
  • 58
    Honma I, Masumori N, Sato E et al. Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors. Urology 2004; 64: 7448.
  • 59
    Tobisu K, Tanaka Y, Mizutani T et al. Transitional cell carcinoma of the urethra in men following cystectomy for bladder cancer: multivariate analysis for risk factors. J. Urol. 1991; 146: 15514.
  • 60
    Tran W, Serio AM, Raj GV et al. Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and potential implications for long-term surveillance. J. Urol. 2008; 179: 96100.
  • 61
    Konety BR, Joslyn SA, O'Donnell MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients with diagnosis with bladder cancer: analysis of data from the surveillance, epidemiology and results program data base. J. Urol. 2003; 169: 94650.
  • 62
    Rödel C, Grabenbauer GG, Kuhn R et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J. Clin. Oncol. 2002; 20: 306171.
  • 63
    Miyanaga N, Akaza H, Hinotsu S et al. Background Variables for Patients with Invasive Bladder Cancer Suitable for Bladder-preserving Therapy. Jpn J. Clin. Oncol. 2007; 37: 8527.
  • 64
    Herr HW, Dotan Z, Donat SM et al. Defining optimal therapy for muscle invasive bladder cancer. J. Urol. 2007; 177: 43743.
  • 65
    Sumiyoshi Y. Chemoradiotherapy as a bladder-preserving approach for muscle-invasive bladder cancer: current status and perspectives. Int. J. Clin. Oncol. 2004; 9: 48490.
  • 66
    Nishiyama H, Habuchi T, Watanabe J et al. Clinical outcome of a largescale multi-institutional retrospective study for a locally advanced bladder cancer: a survey including 1131 patients treated during 1990–2000 in Japan. Eur. Urol. 2004; 45: 17681.
  • 67
    Takahashi A, Tsukamoto T, Tobisu K et al. Radical cystectomy for invasive bladder cancer: results of multi-institutional pooled analysis. Jpn J. Clin. Oncol. 2004; 34: 149.
  • 68
    Hautmann RE, Gschwend JE, De Petriconi RC et al. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J. Urol. 2006; 176: 48692.
  • 69
    Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J. Urol. 2006; 24: 296304.
  • 70
    Stein JP, Cai J, Groshen S et al. Risk factors for patients with pelvic lymph node metastasis following radical cystectomy with en bloc pelvic lymphadenectomy: the concept of lymph node density. J. Urol. 2003; 170: 3541.
  • 71
    Lowrance WT, Rumohr JA, Chang SC et al. Contemporary open radical cystectomy: analysis of perioperative outcomes. J. Urol. 2008; 179: 131318.
  • 72
    Clark PE, Stein JP, Groshen SG et al. Radical cystectomy in the elderly. Comparison of clinical outcomes between younger and older patients. Cancer 2005; 104: 3643.
  • 73
    Schoenberg MP, Walsh PC, Breazeal DR et al. Local recurrence and survival following nerve-sparing radical cystoprostatectomy for bladder cancer: 10-year followup. J. Urol. 1996; 155: 4904.
  • 74
    Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 2001; 19: 66675.
  • 75
    Madersbacher S, Hochreiter W, Burkhard F et al. Radical cystectomy for bladder cancer today – a homogeneous series without neoadjuvant therapy. J. Clin. Oncol. 2003; 21: 6906.
  • 76
    Herr HW, Faulkner JR, Grossman HB et al. Surgical factors influence bladder cancer outcomes; a cooperative group report. J. Clin. Oncol. 2004; 22: 27819.
  • 77
    Lotan Y, Guppa A, Shariat SF et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J. Clin. Oncol. 2005; 23: 65339.
  • 78
    Stenzl A, Bartsch G, Rogatsch H. The remnant urothelium after reconstructive bladder surgery. Eur. Urol. 2002; 41: 12431.
  • 79
    Clark PE, Hall MC. Contemporary management of the urethra in patients after radical cystectomy for bladder cancer. Urol. Clin. North Am. 2005; 32: 199206.
  • 80
    Stein JP, Clark P, Miranda G et al. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J. Urol. 2005; 173: 11638.
  • 81
    Huguet J, Monllau V, Sabate S et al. Diagnosis, risk factors, and outcome of urethral recurrences following radical cystectomy for bladder cancer in 729 male patients. Eur. Urol. 2008; 53: 78593.
  • 82
    Kessler TM, Burkhard FC, Perimenis P et al. Attemted nerve sparing surgery and age have a significant effect on urinary continence and erectile function after radical cystoprostatectomy and ileal orthotopic bladder substitution. J. Urol. 2004; 172: 13237.
  • 83
    Stenzl A, Jarolin L, Coloby P et al. Urethra-sparing cystectomy and orthotopic urinary diversion in women with malignant pelvic tumors. Cancer 2001; 92: 186471.
  • 84
    Vallancien G, Fettouh HAE, Cathelineau X et al. Cystectomy with prostate sparing for bladder cancer in 100 patients:10-year experience. J. Urol. 2002; 168: 241317.
  • 85
    Hautmann RE, Volkmer BG, Schumacher MC et al. Long-term results of standard procedures in urology: the ileal neobladder. World J. Urol. 2006; 24: 30514.
  • 86
    Studer UE, Burkhard FC, Schumacher M et al. Twenty years experience with an ileal orthotopic low pressure bladder substitute-lessons to be learned. J. Urol. 2006; 176: 1616.
  • 87
    Tanaka T, Kitamura H, Takahashi A et al. Long-term functional out-come and late complications of Studer's neobladder. Jpn J. Clin. Oncol. 2005; 35: 3914.
  • 88
    Arai Y, Takeda A, Taki Y et al. 5-year interval change in voiding function of orthotopic ileal neobladder. Int. J. Urol. 2006; 13: 7036.
  • 89
    International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomized controlled trial. Lancet 1999; 354: 53340.
  • 90
    Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 2003; 349: 85966.
  • 91
    Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur. Urol. 2005; 48: 2026.
  • 92
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive-bladder cancer: update of a systemic review and meta-analysis of individual patient data. Eur. Urol. 2005; 48: 189201.
  • 93
    Von Der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 2005; 23: 46028.
  • 94
    MacGregor PS, Montie JE, Straffon RA. Cutaneous ureterostomy as palliative diversion in adults with malignancy. Urology 1987; 30: 314.
  • 95
    Toyoda H. A new technique for catheterless cutaneous ureterostomy. J. Urol. 1977; 117: 2768.
  • 96
    Hirokawa M, Iwasaki A, Yamazaki A et al. Improved technique of tubeless cutaneous ureterostomy and results of permanent urinary diversion. Eur. Urol. 1989; 16: 12532.
  • 97
    Madersbacher S, Schmidt J, Eberle JM et al. Long-term outcome of ileal conduit diversion. J. Urol. 2003; 169: 98590.
  • 98
    Souli M, Straub M, Gam X et al. A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J. Urol. 2002; 167: 13258.
  • 99
    Deliveliotis C, Papatsoris A, Chrisofos M et al. Urinary diversion in highrisk elderly patients: modified cutaneous ureterostomy or ileal conduit? Urology 2005; 66: 299304.
  • 100
    Lehmann J, Retz M, Wiemers C et al. AUO-AB 05/95. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial(AUO-AB 05/95). J. Clin. Oncol. 2005; 23: 496374.
  • 101
    Stöckle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J. Urol. 1992; 148: 3026, discussion 306–7.
  • 102
    Stöckle M, Wellek S, Meyenburg W et al. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 1996; 48: 86875.
  • 103
    Von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 2000; 17: 306877.
  • 104
    Akaza H, Naito S, Usami M et al. Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy: a Japanese experience. Jpn J. Clin. Oncol. 2007; 37: 2016.
  • 105
    Bellmunt J, Von Der Maase H, Mead GM et al. Randomized phase III study comparing paclitaxel/cisplatin,/gemcitabine (PCG) and gemcitabine,/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intersroup Study. ASCO Meeting Abstracts, 2007.
  • 106
    Hussain MH, MacVicar GR, Petrylak DP et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J. Clin. Oncol. 2007; 25: 221824.
  • 107
    Lorusso V, Crucitta E, Silvestris N et al. Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium. Oncol. Rep. 2005; 13: 2837.
  • 108
    Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. 1999; 17: 317381.
  • 109
    Pos FJ, Hart G, Schneider C et al. Radical radiotherapy for invasive bladder cancer: what dose and fractionation schedule to choose? Int. J. Radiat. Oncol. Biol. Phys. 2006; 64: 116873.
  • 110
    Naslund I, Nilsson B, Littbrand B. Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. Acta Oncol. 1994; 33: 397402.
  • 111
    Fossa SD, Waehre H, Aass N et al. Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. Cancer 1993; 15: 303642.
  • 112
    Anderson RS, El-Mahdi AM, Kuban DA et al. Brain metastases from transitional cell carcinoma of urinary bladder. Urology 1992; 39: 1720.
  • 113
    Holmäng S, Borghede G. Early complications and survival following short-term palliative radiotherapy in invasive bladder carcinoma. J. Urol. 1996; 155: 1002.
  • 114
    Roos DE, Turner SL, O'Brien PC et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother. Oncol. 2005; 75: 5463.
  • 115
    Hartsell WF, Scott CB, Bruner DW et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J. Natl. Cancer Inst. 2005; 97: 798804.
  • 116
    Sze WM, Shelley M, Held I et al. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy-a systematic review of the randomised trials. Cochrane Database Syst. Rev. 2004; (2): CD004721.
  • 117
    Salazar OM, Sandhu T, Da Motta NW et al. Fractionated half-body irradiation(HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized Phase III trial of the International Atomic Energy Agency (IAEA). Int. J. Radiat. Oncol. Biol. Phys. 2001; 50: 76575.